Dr. Daniel D. Borgeson, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of North Dakota School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 546
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of North Dakota School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MN license 35346
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Rochester Rochester, MN
Medical groups
- Mayo Clinic (4,956 clinicians)
- Winneshiek Medical Center (101 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 546
- Services billed
- 791
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 492 | 491 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 92 | 50 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 89 | 88 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 87 | 86 |
| Ultrasound of heart, follow-up | 67 | 67 |
| Heart muscle strain imaging | 60 | 60 |
| Established patient office or other outpatient visit, 30-39 minutes | 41 | 38 |
| Ultrasound of heart with probe in esophagus, with report | 35 | 34 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 34 | 33 |
| New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vyndamax (tafamidis) | 95 |
| Vyndaqel (tafamidis meglumine) | 72 |
| Eliquis (apixaban) Other prescribers in Rochester, MN | 40 |
| Torsemide Other prescribers in Rochester, MN | 39 |
| Metoprolol Succinate Other prescribers in Rochester, MN | 39 |
| Atorvastatin Calcium Other prescribers in Rochester, MN | 37 |
| Potassium Chloride Other prescribers in Rochester, MN | 31 |
| Lisinopril Other prescribers in Rochester, MN | 30 |
| Carvedilol Other prescribers in Rochester, MN | 22 |
| Jardiance (empagliflozin) Other prescribers in Rochester, MN | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $78,363 in research payments for these studies, mostly to the institutions running them.
- CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. · Completed · NCT04136171 - An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. · Enrolling by invitation · NCT05667493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.